Document Detail

What is the 'ideal' duration of progesterone supplementation before the transfer of cryopreserved-thawed embryos in estrogen/progesterone replacement protocols?
MedLine Citation:
PMID:  15695314     Owner:  NLM     Status:  MEDLINE    
Different studies dealing with the start of progesterone supplementation in assisted reproduction treatment cycles have shown that the problem apparently is the correct timing. We therefore would like to discuss the data on: (i) the start of progesterone replacement in oocyte donation programmes; (ii) the start of progesterone replacement in frozen-thawed hormone-supplemented cycles; (ii) the problem of too early a rise of progesterone in fresh IVF cycles as a model of too early an administration of progesterone; and (iv) the benefit of high progesterone levels on the day of embryo transfer in fresh IVF cycles. From the data reviewed in this paper it seems to be appropriate to start progesterone administration before transfer in oocyte donation programmes as well as transfer of cryopreserved/thawed cells as soon as the endometrium is developed sufficiently (> or =8 mm, trilaminar pattern), and to perform the embryo transfer not before day 3-4 of progesterone treatment, i.e. embryo development on day 2-3. Studies dealing with the influence of too early a rise of progesterone in fresh IVF cycles have shown different results. In fact high progesterone levels seem to reflect a high response but not a lower probability of conception. Furthermore, high progesterone levels on the day of embryo transfer in fresh IVF cycles could lower myometrial contractility and therefore increase implantation rates. Since the experience from oocyte donation programes shows the benefit of a longer preparation time using progesterone, and high progesterone levels seem to have a benefit during embryo transfer, this would suggest extending progesterone administration before transfer. However, we have to find the optimal individual transfer protocol after mock cycles, for example with pinopode detection or other methods applicable in routine IVF programmes. We need more studies to be sure whether reproductive outcome after transfer of cryopreserved-thawed cells in estrogen/progesterone supplement cycles is influenced by the duration of progesterone pretreatment. If this is so, we must look for practicable methods to modify the protocols according to the individual patient, the embryonic developmental stage during transfer and other variables.
Frank Nawroth; Michael Ludwig
Related Documents :
14609264 - The use of epostane in an attempt to reproduce cystic endometrial hyperplasia in the bi...
21375164 - Manual vacuum aspiration: a safe and cost-effective substitute of electric vacuum aspir...
21235764 - Parental occupational exposure to endocrine disrupting chemicals and male genital malfo...
6634664 - Migration of leucocytes into the uterus after acute removal of ovarian progesterone dur...
3704504 - Influence of pregnancy, birth and abortion on the evolution of systemic lupus erythemat...
12209134 - Natural killer cells and pregnancy.
Publication Detail:
Type:  Journal Article; Review     Date:  2005-02-03
Journal Detail:
Title:  Human reproduction (Oxford, England)     Volume:  20     ISSN:  0268-1161     ISO Abbreviation:  Hum. Reprod.     Publication Date:  2005 May 
Date Detail:
Created Date:  2005-04-22     Completed Date:  2005-08-31     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8701199     Medline TA:  Hum Reprod     Country:  England    
Other Details:
Languages:  eng     Pagination:  1127-34     Citation Subset:  IM    
Endokrinologikum Hamburg, Zentrum für Hormon- und Stoffwechselerkrankungen, Reproduktionsmedizin und Gynäkologische Endokrinologie, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Clinical Trials as Topic
Cryopreservation / methods*
Embryo Transfer*
Endometrium / cytology,  pathology
Estrogens / administration & dosage,  therapeutic use*
Fertilization in Vitro / methods
Oocyte Donation / methods
Progesterone / administration & dosage,  blood,  therapeutic use*
Reg. No./Substance:
0/Estrogens; 57-83-0/Progesterone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Uterine size in women with Turner syndrome after induction of puberty with estrogens and long-term g...
Next Document:  Aneuploidy 12 in a Robertsonian (13;14) carrier: Case report.